BBJ: Does Novartis have a concrete goal to bring more investment and healthcare innovation to Hungary?

Colette Matz: Our ambition is bold: make Hungary a powerhouse for healthcare innovation. Clinical trials aren’t just research; they’re lifelines. They give patients early access to tomorrow’s therapies while strengthening the entire healthcare ecosystem. Physicians gain hands-on experience with cutting-edge science, hospitals sharpen their capabilities, and the system benefits from shared resources and efficiencies that help ease financial pressures.

This year alone, we’re launching 20-25 new clinical trials in Hungary, about 10% of all new studies in the country, keeping us among the top three most active innovators in the country. Hundreds of patients will join these programs, adding to the thousands already benefiting. Each trial represents a significant local investment, covering treatments, diagnostics, and procedures. It’s a win-win: better care for patients, added value for hospitals, and a lighter load on the national healthcare system.

BBJ: The country has been proud of its role in clinical trials and in the global clinical research ecosystem, but the number of trials has decreased in recent times. What is the government doing to better position Hungary as a target for international clinical research investment?

CM: Hungary has long punched above its weight in clinical research, ranking among Europe’s top five countries for trial activity per capita. Yes, global trends (AI-driven modeling, tighter regulations) have shifted the landscape, but Hungary is fighting to stay ahead.

The government and the National Directorate General for Hospitals (OKFŐ) are in active dialogue with industry players, including AIPM [the Association of Innovative Pharmaceutical Manufacturers], to streamline processes and keep Hungary attractive for sponsors. With the ability to treat 2,000-3,000 patients and a stellar track record in compliance and data quality, Hungary remains a trusted partner. Renewed focus on clinical trials as a strategic priority shows the country’s intent: stay competitive, stay relevant, and keep delivering world-class research.

BBJ: What clinical trials is Novartis currently running or planning in Hungary, and what is the Hungarian team’s coordinating role in global company clinical trials?

CM: We’re running trials grounded in some of the most exciting science right here, from radioligand therapies that hunt tumors like precision-guided missiles, to CAR-T treatments that turn a patient’s own cells into cancer-fighting superheroes. Our portfolio spans oncology, hemato-oncology, cardiology, neuroscience, ophthalmology, immunology, dermatology, rheumatology, and rare diseases.

Hungary isn’t just participating; it’s leading. Our team coordinates research across several countries in the region, providing operational expertise and ensuring trials run smoothly. This dual role, local execution and regional leadership, cements Hungary’s reputation as a hub for high-impact innovation.

BBJ: We have often spoken in the past of the almost unique resource Hungary has in terms of centralized and deep medical data. How can this be better used, and can it help with the optimization of patient pathways, treatment options, and protocols? Does more need to be done to encourage cooperation between the public and private sectors?

CM: Hungary’s centralized health data is a goldmine for smarter, faster care. We’re exploring a pilot concept that would connect clinical trial enrollment with the national health data system (EESzT). This means that eligible patients can be identified and enrolled in trials quickly, turning months into days.

The benefits ripple from there: patients get early access to breakthrough therapies, the system optimizes care pathways, and research accelerates. However, to unlock the full potential, I believe that the public and private sectors must work hand in hand. Together, we can transform data into better outcomes, stronger research, and a truly future-ready healthcare system.

BBJ: Breast cancer is the leading cause of death among women in Hungary. What is Novartis doing in terms of health education and screening programs in the country? Is this independent, or do you try to dovetail it with state campaigns?

CM: Breast cancer is personal for us. At Novartis, we’re committed to making early detection easier and less intimidating. One example? Our initiative at the Valley of Arts Festival in Kapolcs, where women aged 40–65 could access free mammography screenings, whether they were festival-goers or local residents. By bringing screenings into a familiar, welcoming setting, we broke down barriers and sparked conversations. These efforts complement national programs, not compete with them. With 8,000 new cases annually and one in eight women affected in their lifetime, early detection isn’t optional; it’s lifesaving.

BBJ: As a female CEO yourself, do you think you are more sensitized to the need to drive progress in women’s health issues such as this?

CM: Yes, it’s personal. Women’s health is a cause I champion because I know the juggling act of life, work, and well-being. Our mission is to make preventive care accessible. We’re breaking barriers, building trust, and bringing care closer to women because when women thrive, families and communities thrive.

BBJ: Does Hungary need to rethink education around breast cancer and screening strategies, not just for women, but society as a whole?

CM: There’s undoubtedly room for reflection. Since COVID-19, mammography participation has dropped to 40–50% of invited women, a signal that more can be done to raise awareness and encourage preventive care. Lowering the screening age to 40 is a step in the right direction, but awareness is key. Protecting women’s health isn’t just a women’s issue; it’s a societal one.

BBJ: How accessible are therapies at all stages across the country? Is there a postcode lottery when it comes to screening and treatment, or is it geographically well-balanced?

CM: Access to therapies is strong nationwide, but outpatient screenings can be patchy in rural areas. The good news? Regulations require imaging within two weeks, and capacity is reserved to meet that standard. Once patients reach a specialist, they can count on receiving the same high-quality care, no matter where they live. When it comes to treatment, Hungary delivers equity.

BBJ: Should more be done to promote the role of women in society in general, and to highlight the importance of lifelong follow-up?

CM: Yes, I believe so. Women often put themselves last. Regular screenings and follow-ups aren’t luxuries; they’re lifesavers. By prioritizing women’s well-being, we strengthen families, communities, and society as a whole.

This article was first published in the Budapest Business Journal print issue of September 19, 2025.